Abstract: The present disclosure relates to methods and systems for characterizing cancer testis antigen burden (“CTAB”), for predicting cancer survival outcomes using CTAB analysis, and for recommending and/or treating cancer using CTAB analysis. Particularly, aspects are directed to measuring expression of a panel of cancer testis antigen (CTA) gene markers in a tissue form a tumor, determining a CTAB based on the measured expression of the CTA gene markers, predicting response of the tumor to immune checkpoint blockade therapy based on the determined CTAB, where the determined CTAB is associated with a predicted favorable response of the tumor to immune checkpoint blockade therapy when the CTAB is ?171, determining an immune checkpoint blockade therapy for the tumor based on the predicted response of the tumor to immune checkpoint blockade therapy, and administering the determined immune checkpoint blockade therapy to the patient.

Abstract: A method, a device and a platform for a dual assay, co-hybridization of labeled nucleic acid molecules utilizing two independent microarray platforms are provided herein. The dual hybridization method and device, including for example, each of a BAC based array and an oligonucleotide array provide simultaneous replication and/or validation of data for a single assay sample and in the same container, using two or more microarray slides.